Following this discovery, other genetic mutations have also been identified and classified, such as the SETBP1, ASXL1, and TET2. The pathways through which these mutations cause their effect have also been identified and have become an aid to theorizing and proving the efficacy of various chemotherapeutic and immunologic agents in the management of CNL. This evidence concerns the gene ASXL1 and chronic neutrophilic leukemia.